Amarin Corp AMRN

NAS: AMRN | ISIN: US0231112063   31/05/2024
0,865 USD (+2,94%)
(+2,94%)   31/05/2024

2 augustus 2023 · Amarin Reports Second Quarter 2023 Financial Results · Persbericht

31 juli 2023 · Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea · Persbericht

26 juli 2023 · Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress · Persbericht

25 juli 2023 · Amarin Receives Positive Recommendation from Spanish Drug Pricing Committee for National Reimbursement of VAZKEPA® (icosapent ethyl) in Spain · Persbericht

20 juli 2023 · Amarin Board of Directors Announces Executive Compensation Program for New President and CEO Patrick Holt · Persbericht

18 juli 2023 · Amarin Appoints Patrick Holt as President and Chief Executive Officer · Persbericht

18 juli 2023 · Amarin Implements Organizational Restructuring to Strengthen the Company While Driving Patient Access to VASCEPA®/VAZKEPA® Globally · Persbericht

21 juni 2023 · Amarin Announces Vascepa® (Icosapent Ethyl) Approved to Reduce Cardiovascular Risk in the Kingdom of Saudi Arabia (KSA) · Persbericht

1 juni 2023 · Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China · Persbericht

12 mei 2023 · Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events · Persbericht

3 mei 2023 · Amarin Reports First Quarter 2023 Financial Results and Provides Business Update · Persbericht

19 april 2023 · Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023 · Persbericht

17 april 2023 · Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors · Persbericht

4 april 2023 · Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health · Persbericht

16 maart 2023 · Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl) · Persbericht

6 maart 2023 · Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC · Persbericht

5 maart 2023 · Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event · Persbericht

1 maart 2023 · Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update · Persbericht

28 februari 2023 · Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand · Persbericht

27 februari 2023 · Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC · Persbericht

Mijn selecties